A series of online, live, public dialogues putting the spotlight on actionable solutions on access to medicines for decision-makers in Europe.
EPHA’s series of online discussions on key access to medicines (A2M) priorities brings together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.
Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.
Find out more about each event below
Getting it right: Recommendations for a European BARDA
8 December | 16:00-17:00 CET
Will the EU be a wise investor in biomedical R&D or a passive donor?
How can we guarantee a public return on public investment?
As the EU considers establishing an Agency comparable to the U.S. Biomedical Advanced Research and Development Authority (BARDA), we will outline a set of recommendations on how to get it right.
The Presidencies' perspective on the pharmaceutical strategy: Europe's to-do list on access to medicines
25 November | 16:00-17:00 CET
The EU’s Pharmaceutical Strategy is due to be published on 24 November by the European Commission.
Senior representatives of the upcoming Presidencies of the EU (Portugal & Slovenia) and the Netherlands, will offer their perspective on what should be prioritised and debate the next steps in European pharmaceutical policy
Pharma & COVID19: Winners, losers, prospects
19 November | 16:00-17:00 CET
Is the affordability debate in Europe changing in the light of COVID19?
Who are the big winners and losers?
Join a venture capitalist investing in pharma; a leading access to medicines advocate; an expert in the science and economics of drug R&D; and the advocacy director of an alternative drug development model to discuss how COVID19 has reshaped the dynamics within the sector, as well as between industry and European governments.
The EU's IP strategy: Enabler or barrier?
How do we ensure that IP incentives compensate and reward innovation but do not distort competition?
What lessons have we learned on IP in the response to COVID19?
Our experts and key stakeholders will discuss what change is necessary to serve the needs of all patients while guaranteeing healthy prices and competition
Unleashing meaningful innovation through regulatory reform